Roundtable Digital

AI in Pharma: Transforming the Future of Sales Excellence and Operations

Unlocking The Potential of Artificial Intelligence in Pharma

October 8, 2024, 12:00 – 1:00 p.m. (CET)

Be part of this exclusive roundtable to understand how AI can solve complex problems and drive innovation in the pharmaceutical sector. This is an unmissable opportunity for professionals looking to stay ahead in the rapidly evolving world of AI and pharma.

j

Event

Digital via Livestream

October 8, 2024, 12:00 – 1:00 p.m. (CET)

Welcome and introduction of speakers
What is AI? Jack Lampka will provide an overview of artificial intelligence, explaining key concepts like artificial general intelligence, machine learning, deep learning, and generative AI.
AI in Sales and Marketing: Jack Lampka will explore the use of AI in customer profiling, natural language processing, HCP insights, resource optimization, and predictive analytics, highlighting its potential to optimize sales and marketing strategies.
Challenges with AI in Pharma Operations: Dr. Maximilian Pinker will address the regulatory challenges and operational hurdles faced when implementing AI in pharma, offering practical solutions to overcome these barriers.
Q&A Session: Engage with our experts in an interactive Q&A session to clarify doubts and gain deeper insights into AI applications in the pharmaceutical industry.

l

Topic

Join us for an insightful roundtable discussion, “AI for Pharma,” where two distinguished experts will delve into the transformative impact of artificial intelligence on the pharmaceutical industry. This event is designed to raise awareness about AI and its applications in pharma, providing attendees with valuable knowledge and actionable insights.

Our Experts:

Jack Lampka, AI Keynote Speaker & Advisor
Dr. Maximilian Pinker, Independent Consultant

k

Registration

We look forward to your participation. Reserve your place:

Register now

Our keynote speakers

Jack Lampka simplifies and demystifies complex artificial intelligence (AI) topics for executives and data leaders to gain business value from AI, with pragmatism built on 27 years of data & AI expertise. Based on his successes and failures, he is delivering keynotes and advising companies on the human factor of AI adoption.

Jack has built and led data teams, developed data strategies, and accelerated AI adoption. He has enabled companies to turn data into business impact, supported executives with data-driven decisions, and cultivated data mindset through data literacy programs. All that has started after his MBA from the University of Washington in Seattle, USA and Master of Science in Electrical Engineering from RWTH Aachen, Germany and continued in several doer and then ten years of leader roles at large high-tech companies (Tektronix & HP in the USA), pharma (MSD in Germany), and a startup in between.

Dr. Maximilian Pinker is an experienced leader in the pharmaceutical and biotech industries, renowned for leading complex change projects and driving organizational excellence. With a pragmatic approach developed through years of leadership roles, Dr. Pinker provides strategic and technical consulting that enhances efficiency, quality, and cost-effectiveness in operations, quality management, and project management.

Dr. Pinker focuses on organizational and process optimization, culture change, digital transformation, multi-site harmonizations, and inspection readiness and remediation programs.

Throughout his career, he has led multinational and global projects involving up to 500 heads and managed projects valued up to €50 million annually. He has led strategic initiatives that yielded million-euro savings. He has provided multi-site quality leadership, including at Europe’s largest COVID-19 PCR testing organization. He has directed various digital transformation projects, such as implementing eQMS, LIMS, and DMS systems, and successfully introduced Lean Six Sigma in QC departments across 15 pharmaceutical manufacturing sites. Dr. Pinker has a proven track record of securing successful inspections by the US-FDA and other authorities.